-+ 0.00%
-+ 0.00%
-+ 0.00%

Taiyu Pharmaceutical submitted a clinical trial application for an antibody-drug conjugate biosimilar TSY-110 for HER2-positive breast cancer.

Zhitongcaijing·08/28/2026 12:09:11
Listen to the news
Taiyu Pharmaceutical submitted a clinical trial application for an antibody-drug conjugate biosimilar TSY-110 for HER2-positive breast cancer.